Bevacizumab Biosimilar Vial for Oncology from Germany
Avastin biosimilar bevacizumab, a VEGF monoclonal antibody in 100mg/4ml vials for retail infusion in cancer treatment, modulating angiogenesis via immune regulation. Fits HTS 3002.15.00.91 for MAB immunological products in measured doses.
Duty Rate — Germany → United States
15%
Rate breakdown
9903.04.6215%Patented pharmaceutical articles that are the product of Japan, of a European Union member country, of South Korea, of Switzerland, or of Liechtenstein as provided for in subdivisions (c) and (f) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
9903.05.900%Articles of aluminum, of steel or of copper or derivative aluminum or steel articles; passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; parts of passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; medium- and heavy-duty vehicles; parts of medium- and heavy-duty vehicles; wood products; patented pharmaceutical articles; and semiconductor articles, as provided in subdivision (f) of U.S. note 52 to this subchapter
Import Tips
• Biosimilars need comparative efficacy data; FDA 351(k) pathway docs essential
• Use insulated packaging with data loggers for uninterrupted cold chain